Holen Sie sich die Stockscreener-App
1.2611
3.76%
-0.0689
Schlusskurs vom Vortag:
$1.33
Offen:
$1.28
24-Stunden-Volumen:
98,097
Relative Volume:
0.29
Marktkapitalisierung:
$6.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.68M
KGV:
-0.1705
EPS:
-7.3948
Netto-Cashflow:
$-15.70M
1W Leistung:
-2.29%
1M Leistung:
-6.57%
6M Leistung:
-80.91%
1J Leistung:
-92.82%
1-Tages-Spanne:
$1.22
$1.291
1-Wochen-Bereich:
$1.22
$1.51
52-Wochen-Spanne:
$1.03
$22.60
Fibrobiologics Inc Stock (FBLG) Company Profile
Firmenname
Fibrobiologics Inc
Sektor
Branche
Telefon
281-671-5150
Adresse
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.27 | 6.93M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
428.62 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.02 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.88 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.12 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-24 | Eingeleitet | Maxim Group | Buy |
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Canada
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics CEO Issues Letter to Shareholders - 富途牛牛
FibroBiologics Grants Stock Options to Key Executives - TipRanks
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years - Stock Titan
FibroBiologics (FBLG) CSO granted 61,607 stock options at $1.38 - Stock Titan
FibroBiologics (FBLG) CFO awarded 61,607 stock options at $1.38 - Stock Titan
FibroBiologics grants options to general counsel | FBLG Insider Trading - Stock Titan
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com Australia
FibroBiologics reports preclinical burn wound treatment results - Investing.com
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - The Manila Times
In mice, a topical cell treatment eased burn inflammation in 8 days - Stock Titan
FibroBiologics releases first batch of diabetic ulcer drug By Investing.com - Investing.com South Africa
Maxim Group Downgrades FibroBiologics(FBLG.US) to Hold Rating - Moomoo
FibroBiologics releases first batch of diabetic ulcer drug - Investing.com
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - The Manila Times
Diabetic foot ulcer trial nears enrollment as drug batch clears tests - Stock Titan
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
Certain Common Stock of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
Certain Stock Options of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens - TipRanks
FibroBiologics Launches New At-The-Market Equity Offering - TipRanks
Regenerative medicine company FibroBiologics (stock code: FBLG) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that it has signed an At Market Issuance (ATM) agreement. - Bitget
[424B5] FibroBiologics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
FibroBiologics (NASDAQ: FBLG) sets up $6,150,000 at-the-market stock program - Stock Titan
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Reports Q1 2026 Financial Results and Corporate Updates on Clinical Advancements - Quiver Quantitative
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FibroBiologics (FBLG) low cash, $5M loss and going concern risk - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Preclinical psoriasis data from FibroBiologics heads to Chicago meeting - Stock Titan
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - The Manila Times
FibroBiologics (FBLG) price target decreased by 76.25% to 19.38 - MSN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics (FBLG) price target increased by 1,584.21% to 81.60 - MSN
Return on invested capital % of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics (FBLG) asks shareholders to OK March warrant issuances, equity plan - Stock Titan
FibroBiologics regains Nasdaq compliance on listing standards By Investing.com - Investing.com India
FibroBiologics regains Nasdaq compliance on listing standards - Investing.com
FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring - TipRanks
Fibrobiologics compliant with all Nasdaq listing requirements - marketscreener.com
Finanzdaten der Fibrobiologics Inc-Aktie (FBLG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrobiologics Inc-Aktie (FBLG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
| Khoja Hamid | Chief Scientific Officer |
May 27 '25 |
Buy |
0.84 |
20,000 |
16,800 |
31,250 |
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):